Successful track record of developing and commercializing innovative and clinically significant healthcare technologies.
President and CEO
31 years of healthcare experience, 25 of which have been within the medical devices sector in numerous global leadership roles with a proven track record of market development and sales and marketing execution and an extensive global network in GI, Bariatrics and Diabetes. Served as Vice President of International Sales and Marketing at Apollo Endosurgery and was an officer of the company Apollo Endosurgery; Smith and Nephew; ArthroCare Corporation
Chief Financial Officer
Jane Wright was appointed Chief Financial Officer of Morphic Medical in August 2025, bringing over 30 years of finance and operations leadership. CIMA-qualified since 1994, she has spent the past 18 years in senior positions within international medical device companies, combining deep financial expertise with a commitment to operational excellence. She has a proven record of building global infrastructures, enhancing efficiency, ensuring regulatory compliance, and delivering transformative change, most notably at Apollo Endosurgery and ArthroCare Corporation.
Vice President of Clinical, Regulatory and Quality
Stephen brings over 30 years of experience in development, regulatory, preclinical and clinical operations, quality and resource management with a focus on medical devices.
Prior to joining Morphic Medical, Stephen held the position of vice president of regulatory, clinical affairs and quality assurance at Neograft Technologies Inc. He also held leadership roles at Insulet Corporation, Boston Scientific Corporation Inc., and Phase Forward Inc., as well as vice president roles at PLC Medical Systems.
Stephen brings extensive knowledge of the diabetes disease and medical device space, where he has led 10 clinical trials, multiple CE Mark approvals, and numerous 510(k) clearances. Stephen holds nearly 20 United States and international patents and co-author of two peer-reviewed publications.
Stephen holds a BS in Physics from Bridgewater State College.
Sr. Director, Research & Development
Chris has focused the last 25 years of his career on honing exactly one skillset: driving innovative solutions in the medical device industry. He has predominately worked in the engineering, research and development functions as both a technical and program leader. He has also spent some time as an upstream marketer and a strategic planner.
Prior to joining the Morphic Medical team, Chris ran his own boutique consulting firm, TWC Group, which focused on training leaders to be not only more innovative in their approach, but more authentic in how they lead. Prior to that, Chris held leadership positions at Minnetronix Medical, Avanos Medical, Halyard Health, Kimberly-Clark Healthcare, and Coloplast A/S.
Chris not only brings extensive experience in medical device development, but also experience as a medtech entrepreneur, with multiple successful medtech start-up exits in his history. He has helped launch over 50 devices into the marketplace, is named on over 30 US and Global patents, co-authored a peer-reviewed publication, and contributed an ASTM standard.
He holds degrees in Biomedical Engineering and Business Administration.
Director of Quality Assurance
Don has been active for 40 years in the Medical Device Quality Assurance area in the development and management of Quality Management Systems, creating value through Quality System excellence, process improvement, and compliance with EU and FDA regulations.
Prior to joining Morphic Medical, Don was Global Quality Systems Manager at Haemonetics, responsible for worldwide Quality Systems, Process Improvement, and compliance. Don has worked for Leica Microsystems, Siemens, and Johnson & Johnson, as well as a long list of start-up firms.
Don brings an extensive knowledge of Lean/Six Sigma methodologies along with expert level knowledge of Medical Device Regulations having achieved CE for several products (including a product he designed), bringing non-compliant companies into regulatory compliance and increasing Quality Systems efficiency and effectivity.
Don holds a BS in Mechanical Engineering from U-Mass Amherst.
Sr. Director, Sales and Marketing International
Joined Morphic Medical as Senior Director, Sales & Marketing, International, in October 2025. He has 17 years experience in the medical device industry after working in corporate finance and banking. Mark has extensive experience in the international commercialization of medical devices, leading sales across over 60 countries globally as well as numerous new product launches across Europe, Asia, Latin America and Africa. Prior career highlights include Arthrocare, Smith & Nephew, Apollo Endosurgery and Boston Scientific.
The Morphic Board of Directors is committed to carrying out our mission of improving the lives of people suffering from the global epidemics of type 2 diabetes and obesity through the development and commercialization of breakthrough treatments.
Chairman
Dr Terri Cooper is a 35-year life sciences-healthcare industry veteran. As a recognized life sciences-healthcare expert, Terri has worked across sectors globally in both public and private domains. Terri is a former Principal of Deloitte’s US consulting practice. Her experience spans complex industry, business, technology, brand-building, and regulatory imperatives. She has successfully built Deloitte’s Life Sciences R&D business and has led global organisational and financial restructures driving significant performance improvement, and has piloted innovation and M&A initiatives that have resulted in growth opportunities and competitive differentiation.
Member of the Board of Directors
John Barr is the former Chairman of the Board for Apollo Endosurgery, now part of Boston Scientific, and former Operating Partner for Altamont Capital Partners, a private equity firm. Prior, Mr. Barr served on the Board of Directors of Valeritas Holdings Inc., a medical technology company focused on the treatment of diabetes. Previous positions include serving as CEO of Surgical Specialties, Inc., a manufacturer of surgical instruments, and President, Global Surgical at Bausch & Lomb Holdings Incorporated, an eye health products company.
Member of the Board of Directors
Ginger Glaser brings over 25 years of quality and regulatory experience, leading successful medical device organizations, as well as a breadth of knowledge in clinical affairs and engineering. She currently is the Principal for G2 Consulting Services and the Chief Technology Officer for Monteris Medical, where she previously held vice president positions. Ms. Glaser held vice president roles with Boston Scientific and American Medical Systems, prior to its acquisition by Boston Scientific.
Ms. Glaser has a strong understanding of FDA processes and culture. She has led industry-wide task forces and helped numerous organizations obtain global regulatory approvals, including “first in the world” achievements.
Ms. Glaser graduated Cum Laude from Texas A&M University, where she earned her B.S. in Bioengineering and M.S. in Biomedical Engineering.
Member of the Board of Directors
Craig Richardson is an internationally recognized healthcare executive with more than four decades of leadership experience helping innovative healthcare companies transform breakthrough technologies into commercial success. His career spans global pharmaceutical, medical device, digital health, and healthcare data organizations, where he has consistently delivered growth through strategic leadership, market access, evidence generation, and organizational transformation.
Craig has held senior executive leadership positions with Johnson & Johnson and Novartis, leading global initiatives across commercialization, health economics, reimbursement, real-world evidence, business intelligence, digital health, and corporate strategy. He has built new organizational capabilities, led international teams, developed strategic partnerships with healthcare providers, regulators, payers, and academic institutions, and supported products representing multi-billion-dollar global franchises.
Throughout his career, Craig has been at the forefront of healthcare innovation. He played a leadership role in advancing electronic prescribing in the United States, contributed to the development of national health information infrastructure, and partnered with regulators and industry leaders to improve the use of healthcare data in clinical and commercial decision-making. At Novartis, he co-developed the company’s Global Real-World Evidence capability, generating the evidence needed to support physician adoption, payer access, and long-term commercial success for one of the company’s flagship immunology brands.
Craig now advises emerging healthcare and medical technology companies on commercialization strategy, reimbursement, market access, evidence generation, and organizational growth. As a Non-Executive Director, he brings an uncommon combination of strategic vision, governance experience, commercial execution, and deep understanding of how clinical evidence, physician adoption, regulatory strategy, and reimbursement align to create sustainable enterprise value.
His particular interest is supporting companies developing innovative therapies for obesity, diabetes, metabolic disease, gastrointestinal disorders, and other areas where breakthrough technologies have the potential to transform patient care and healthcare economics.
Morphic is privileged to have as our scientific advisors a prestigious, multidisciplinary group of leaders dedicated to advancing research for the treatment of type 2 diabetes, obesity and other metabolic disorders.
Endocrinologist, Seattle, WA, U.S.A.
Dr. Cummings is a Professor of Medicine in the Division of Metabolism, Endocrinology and Nutrition at the University of Washington, based at the Diabetes & Obesity Center of Excellence and the V.A. Puget Sound Health Care System. He studies the hormonal and neurochemical pathways that regulate appetite, body weight and glucose homeostasis by using experiments ranging from bench science to clinical investigation. A major current focus of his research is to elucidate endocrine mechanisms that mediate the profound effects of bariatric/metabolic surgery on diabetes and body weight, as well as to determine the role of surgery in diabetes care through randomized clinical trials.
Dr. Cummings is a summa cum laude graduate of Dartmouth College, where he majored in biochemistry. He obtained his medical degree from Harvard Medical School and the Massachusetts Institute of Technology. He is a recipient of the Presidential Early Career Award for Scientists and Engineers—the highest award conferred by the US government to researchers in their early independent careers.
Endocrinologist, New York, NY, U.S.A.
“Our research has shown there is a need for new treatment options for type 2 diabetes and obesity as we see rates continue to rise throughout the world. Specifically, we have shown that despite significant effort to optimize lifestyle and dietary counseling in conjunction with the utilization of diabetes medication, significant limitations exist that can be addressed with innovative interventional approaches. I am eager to aid in the development of EndoBarrier with GI Dynamics and the SAB as it has shown promising results.”
Endocrinologist, Dublin, Ireland
Professor Le Roux serves as the head of pathology at the University College Dublin in Ireland. He graduated from medical school in Pretoria, South Africa, where he completed his specialist training in metabolic medicine at St. Bartholomew’s Hospitals and Hammersmith Hospitals. He completed his PhD at Imperial College London and was later promoted to Reader. He received a Clinician Scientist Award from the UK National Institute of Health Research and a Wellcome Trust Clinical Research Fellowship for his work on how the gut communicates with the brain.
Bariatric/Metabolic Surgeon, Sao Paulo, Brazil
Dr. Cohen is the director for the Center for Obesity and Diabetes at the Oswaldo Cruz German Hospital located in São Paulo, Brazil. Dr. Cohen is also the former president of the Brazilian Society of Bariatric and Metabolic Surgery, and is the current president of the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO), Latin America Chapter.
Dr. Cohen has been the primary investigator (PI) for 15 studies, including two EndoBarrier studies. He has published more than 150 papers and is considered a leader in the field of surgery for patients with type 2 diabetes and non-severe obesity.
Bariatric/Metabolic Surgeon, Heerlen, Netherlands
Dr. Greve serves as medical director of the Dutch Obesity Clinics South and chair of the Metabolic and Bariatric Surgery Unit at the Zuyderland Medical Center in the Netherlands. Dr. Greve received his PhD at the Academic Hospital in Maastricht, Netherlands, has served on numerous committees, supervised 15 doctoral theses and authored more than 185 peer-reviewed papers and numerous book chapters on intensive care medicine, nutrition and bariatric and metabolic surgery. He was principal investigator of two European EndoBarr.
Bariatric/Metabolic Surgeon, London, UK
Dr. Rubino is internationally recognized as one of the world leaders in the research, education, and practice of metabolic and weight-loss surgery. He received his MD and completed his residency in general surgery at the Catholic University in Rome, Italy. Dr. Rubino completed fellowships in laparoscopic surgery at the European Institute of Telesurgery in Strasbourg, France, at Mount Sinai Medical Center, New York, and at the Cleveland Clinic.
A member of many professional organizations, Dr. Rubino is the recipient of numerous awards, has given hundreds of presentations throughout the world, and is the author of over 100 articles in peer-reviewed journals as well as numerous book chapters. His experimental studies provided the first evidence of a direct effect of gastrointestinal surgery on glucose metabolism independent of weight loss, uncovering a biological link between the gut and diabetes. Dr. Rubino was the main organizer and co-director with Dr. Lee Kaplan and GI Dynamics SAB members Dr. Cummings and Dr. Schauer of the Diabetes Surgery Summit (DSS), an influential consensus conference. The recently released DSS guidelines have been adopted by the American Diabetes Association, and have been endorsed by over 50 scientific societies around the world. Dr. Rubino also served as Congress Director and organizer of the first three editions of the World Congress on Interventional Therapies for Type 2 Diabetes, an international forum for discussion of both conventional surgical interventions and novel endoluminal approaches.
Professor of Metabolic Surgery, Baton Rouge, Louisiana, U.S.A
Dr. Philip Schauer is the Mary Kay and Terrell Brown endowed Professor of Metabolic Surgery at Pennington Biomedical Research Center of Louisiana State University in Baton Rouge, Louisiana and Professor of Surgery at LSU HSC New Orleans. He is Director of the MetamorTM Metabolic Institute at Pennington Biomedical. He is formerly Professor of Surgery at the Cleveland Clinic Lerner College of Medicine. He is past president of the American Society for Metabolic & Bariatric Surgery (ASMBS). He is former Chair and founder of Obesity Week (2012-present) and Co-Chair of the Diabetes Surgery Summit (2007, 2015, 2019).
Gastroenterologist, SAo Paulo, Brazil
Dr. Galvao is a clinical associate professor at Herbert Wertheim College of Medicine at Florida International University in Miami, Florida, and Affiliate Professor of Surgery at ABC College of Medicine in Canto Andrew in Sao Paulo, Brazil. Galvao earned his PhD at the Federal University of Pernambuco, Brazil, in 2018 for his thesis on endoscopic treatment of sleeve gastrectomy leaks.
Dr. Galvao is a board-certified specialist in digestive surgery, gastroenterology and digestive endoscopy with a vast understanding of bariatric endoscopy. He holds multiple positions focused on aiding in the understanding and improvement of quality patient care through bariatric endoscopy.
Nephrology, Indianapolis, IN, U.S.A.
“I am pleased to work with GI Dynamics in broadening their focus to include CKD. I look forward to working with this talented group of clinicians on the GI Dynamics SAB and achieving my goal of improving patient outcomes in the important and ever-growing field of type 2 diabetes- and obesity-related kidney disorders.”
Morphic Medical is currently enrolling patients for its STEP-1 clinical study of RESET® in the United States. Learn more if you or someone you know are interested in participating in the study and would like to see if you qualify to join.
Learn more